Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7221175 | 0.81 | HSD11B1 (0.33) | HSD11B1 | |
| SCHEMBL1512245 | 0.77 | — | — | |
| SCHEMBL9492073 | 0.77 | — | — | |
| SCHEMBL7529469 | 0.71 | APLNR (0.33) | — | |
| SCHEMBL295067 | 0.69 | HSD11B1 (0.32) | HSD11B1 | |
| SCHEMBL6686714 | 0.68 | — | — | |
| SCHEMBL6682945 | 0.68 | HSD11B1 (0.31) | HSD11B1 | |
| SCHEMBL809459 | 0.65 | — | — | |
| SCHEMBL7570194 | 0.60 | — | — | |
| SCHEMBL8405185 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10130634-B2 | Therapeutic agent for ophthalmic disease | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-11-20 | — | — | US | disclosed |
| US-20160193217-A1 | THERAPEUTIC AGENT FOR OPHTHALMIC DISEASE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-07-07 | — | — | US | disclosed |
| US-7935700-B2 | Morpholine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20070265257-A1 | Morpholine Compound | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-15 | — | — | US | disclosed |
| EP-1801108-A1 | MORPHOLINE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2007-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10130634-B2 | Therapeutic agent for ophthalmic disease | MITF, UACA, VEGFA | HSD11B1 604/4885 |
| US-20160193217-A1 | THERAPEUTIC AGENT FOR OPHTHALMIC DISEASE | MITF, UACA, VEGFA | HSD11B1 604/4885 |
| US-20070265257-A1 | Morpholine Compound | CCR3, CCR1, CCR4 | HSD11B1 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.